Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk.

[1]  M. Price,et al.  One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients , 2020, Circulation. Cardiovascular interventions.

[2]  Deepak L. Bhatt,et al.  Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents , 2020, Circulation.

[3]  M. Price,et al.  Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention , 2019, Circulation.

[4]  E. Vicaut,et al.  Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation: A Pairwise Meta-Analysis of 6 Trials and 21 457 Patients , 2019, Circulation. Cardiovascular interventions.

[5]  Deepak L. Bhatt,et al.  Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. , 2019, Journal of the American College of Cardiology.

[6]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[7]  Kenji Inoue,et al.  Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. , 2017, JACC. Cardiovascular interventions.

[8]  Deepak L. Bhatt,et al.  Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients , 2017, European heart journal.

[9]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[10]  S. Pocock,et al.  Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. , 2016, Journal of the American College of Cardiology.

[11]  F. Eberli,et al.  Polymer-free Drug-Coated Coronary Stents. , 2016, The New England journal of medicine.

[12]  Giuseppe Biondi-Zoccai,et al.  Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.

[13]  Walter Desmet,et al.  ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.

[14]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[15]  J. Wójcik,et al.  6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. , 2015, Journal of the American College of Cardiology.

[16]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[17]  Antonio Colombo,et al.  Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.

[18]  Deepak L. Bhatt,et al.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.

[19]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[20]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 2 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  Y. Jang,et al.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.

[22]  J. Marchesini,et al.  Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.

[23]  M. Jeong,et al.  Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.

[24]  Patrick Royston,et al.  How should variable selection be performed with multiply imputed data? , 2008, Statistics in medicine.

[25]  R. D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions , 2004, Statistics in medicine.

[26]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[27]  Jason P. Fine,et al.  Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .